+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Induced Pluripotent Stem Cells Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • June 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5617149
The Induced Pluripotent Stem Cells Market is projected to register a CAGR of 8.4% during the forecast period (2022 to 2027).

The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to ​reduce the risk of viral transmission as most chronic therapies were regarded as non-urgent. Several research studies were suspended during the COVID-19 period. However, research on the SARS-CoV-2 infection propelled significantly during the pandemic. An article titled "Induced pluripotent stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019" published in the journal of Cytotherapy in March 2022 studied the modeling of SARS-CoV-2 infection in the human context to facilitate drug screening and discovery. With the various research studies being conducted on the use of human cell lines for vaccine development against the SARS-CoV-2 virus, the article showed that the iPSC-derived alveolar-type cells exposed to the SARS-CoV-2 virus would serve as an invaluable tool that can reproduce the genotypic and phenotypic aspects more closely associated with the infection.

Another article published in the International Journal of Molecular Science in December 2021 titled "Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases" studied the recent developments in innovative stem cell and gene editing therapeutic approaches. The article indicated that the iPSCs technology applied using the latest gene-editing methods (CRISPR-Cas9) represents the current emerging field. Clinical trials with iPSCs on the therapeutic application of stem cell therapy are associated with the generation of HLA-compatible iPSCs. The rise in the number of studies involving induced pluripotent stem cells is likely to propel the growth of the market in the forecast period.

In addition, the rise in the prevalence of personalized medicines for various disease treatments is adding to the growth of the induced pluripotent stem cell market. An article titled "Precision regenerative medicine" published in the journal of Stem Cell Research & Therapy in January 2021 discussed the increase in precision or individualized medicine in the medical and surgical disciplines. The article showed that induced pluripotent stem cells are of great importance in the personalized medication segment, as they offer several advantages over other stem cells. Since the induced pluripotent stem cells for treating a person are grafted from the same person, donor variability is prevented, so autoimmune reactions to the treatment can be prevented. Moreover, the increasing number of cancer cases over the years is expected to contribute to the growth of the studied market. An article titled "Pluripotent Stem Cells: Cancer Study, Therapy, and Vaccination" presented in the journal of Stem Cell Reviews and Reports in June 2021 studied the role of pluripotent stem cells in cancer therapy. The article stated that the resemblance of cancer stem cells to pluripotent stem cells can provide an appropriate source of cancer stem cell-specific antigens through the cultivation of pluripotent stem cells, which brings to light promising ideas for prophylactic and therapeutic cancer vaccine development. Thus, the rise in research studies involving cancer treatment using stem cell therapies is adding to the growth of the market in the forecast period.

Additionally, in January 2022, Bayer’s BlueRock Therapeutics reported the dose administration for the first patient in Canada in partnership with the University Health Network in Phase 1 (Ph1), an open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The study was conducted to evaluate the safety, tolerability, and preliminary efficacy of iPSC-derived dopaminergic neurons in Parkinson's affected patients. Such studies involving induced pluripotent stem cells are fueling the market growth in the study period.

Thus, these aforementioned factors are likely to bolster the market's growth over the forecast period. However, a lack of awareness regarding stem cell therapies and higher costs of treatment are projected to hinder the market's growth.

Key Market Trends

The Drug Development Segment is Expected to Hold a Major Market Share in the Induced Pluripotent Stem Cells Market.

By application, the drug development segment holds the major segment in the induced pluripotent stem cell market. Various research studies focusing on drug development studies with induced pluripotent stem cells have been on the rise in recent years. For instance, an article titled "Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening" published in the International Journal of Molecular Science in October 2020 discussed the broad use of iPSC derived cardiomyocytes for drug development in terms of adverse drug reactions, mechanisms of cardiotoxicity, and the need for efficient drug screening protocols. Another article published in the Journal of Cells in December 2021 titled "Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective" focused on methods to reprogram somatic cells into human induced pluripotent stem cells and the solutions to overcome the immaturity of the human induced pluripotent stem cells derived cardiomyocytes to mimic the structure and physiological properties of adult human cardiomyocytes to accurately model disease and test drug safety. Thus, this increase in the research of induced pluripotent stem cells for drug development and drug modeling is likely to propel the segment's growth over the study period.

Furthermore, as per an article titled "Advancements in Disease Modeling and Drug Discovery Using iPSC-Derived Hepatocyte-like Cells" published in the Multi-Disciplinary Publishing Institute journal of Cells in March 2022, preserved differentiation and physiological function, amenability to genetic manipulation via tools such as CRISPR/Cas9, and availability for high-throughput screening, make induced pluripotent stem cell systems increasingly attractive for both mechanistic studies of disease and the identification of novel therapeutics. The article discussed the recent advancements in iPSC-based models of liver disease, including improvements in model system construction as well as the use of high-throughput screens for genetic studies and drug discovery. The study stated that the number of diseases which can be successfully modeled with hepatocyte-like cells derived from induced pluripotent stem cells is continually expanding, thereby developing a deeper understanding of various diseases and the discovery of new treatments for such diseases.

Additionally, several biotechnology companies have also been focusing on induced pluripotent cell-based drug therapies for various diseases. For instance, in February 2022, Edigene, Inc. and Neukio Biotherapeutics entered into a research and development collaboration to develop next-generation immune cell therapies based on the development and manufacturing of induced pluripotent stem cells (iPSC) and natural killer cells (NK Cell).

Thus, the abovementioned factors are altogether contributing to the segment's growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The rise in the adoption of highly advanced technologies and systems in drug development, toxicity testing, and disease modeling coupled with the growing acceptance of stem cell therapies in the region are some of the major factors driving the market growth in North America.

The United States Food and Drug Administration in March 2022 discussed the development of strategies to improve cell therapy product characterization. The agency focused on the development of improved methods for testing stem cell products to ensure the safety and efficacy of such treatments when used as therapies. Likewise, in March 2020, the Food and Drug Administration announced that ImStem drug IMS001, which uses AgeX’s pluripotent stem cell technology, would be available for the treatment of multiple sclerosis. Similarly, REPROCELL introduced a customized iPSC generation service in December 2020, as well as a new B2C website to promote the "Personal iPS" service. This service prepares and stores an individual's iPSCs for future injury or disease regeneration treatment.

Thus, the increasing necessity for induced pluripotent stem cells coupled with increasing investment in the health care department is known to propel the growth of the market in this region.

Competitive Landscape

The Induced Pluripotent Stem Cells Market is competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market areAxol Bioscience Ltd., Cynata Therapeutics Limited, Evotec SE, Fate Therapeutics, Inc., FUJIFILM Cellular Dynamics, Inc., Ncardia, Pluricell Biotech, REPROCELL USA, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takara Bio, Inc., Thermo Fisher Scientific, Inc. ViaCyte, Inc. and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and market definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Research and Development Activities in Stem Cells Therapies
4.2.2 Surge in Adoption of Personalized Medicine
4.3 Market Restraints
4.3.1 Lack of Awareness Regarding Stem Cell Therapies
4.3.2 High Cost of Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Derived Cell Type
5.1.1 Hepatocytes
5.1.2 Fibroblasts
5.1.3 Keratinocytes
5.1.4 Neurons
5.1.5 Others
5.2 Application
5.2.1 Drug Development
5.2.2 Regenerative Medicine
5.2.3 Toxicity Testing
5.2.4 Tissue Engineering
5.2.5 Cell Therapy
5.2.6 Disease Modeling
5.3 End User
5.3.1 Research Institutions
5.3.2 Other End Users
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Axol Bioscience Ltd.
6.1.2 Cynata Therapeutics Limited
6.1.3 Evotec SE
6.1.4 Fate Therapeutics, Inc.
6.1.5 FUJIFILM Cellular Dynamics, Inc.
6.1.6 Ncardia
6.1.7 LizarBio Therapeutics (Pluricell Biotech)
6.1.9 Sumitomo Dainippon Pharma Co., Ltd.
6.1.10 Takara Bio, Inc.
6.1.11 Thermo Fisher Scientific, Inc.
6.1.12 ViaCyte, Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia
  • LizarBio Therapeutics (Pluricell Biotech)
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.